Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Niculescu-Duvaz

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Idrugs : the Investigational Drugs Journal|July 21, 2005
NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The NetherlandsI Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2001
Thymitaq (Zarix)I Niculescu-Duvaz
Idrugs : the Investigational Drugs Journal|May 10, 2008
Recent advances in anticancer drugsI Niculescu Duvaz
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: gemtuzumab ozogamicin, Celltech GroupI Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|March 16, 2001
ZD-9331 AstraZenecaI Niculescu-Duvaz
Neoplasma|January 1, 1982
Potential anticancer agents. XXIII. 2. Quantitative structure--activity relationships (QSAR) in the "classical" antifolates areaI Niculescu-Duvaz, T Craescu
The Journal of Clinical Investigation|May 3, 2000
Prodrug-activating systems in suicide gene therapyC J Springer, I Niculescu-Duvaz
Expert Opinion on Investigational Drugs|June 1, 1997
Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinationsI Niculescu-Duvaz, C J Springer
Anti-Cancer Drug Design|July 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugsC J Springer, I Niculescu-Duvaz
Advances in Experimental Medicine and Biology|May 16, 2000
Approaches to gene-directed enzyme prodrug therapy (GDEPT)C J Springer, I Niculescu-Duvaz
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Idrugs : the Investigational Drugs Journal|July 21, 2005
NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The NetherlandsI Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2001
Thymitaq (Zarix)I Niculescu-Duvaz
Idrugs : the Investigational Drugs Journal|May 10, 2008
Recent advances in anticancer drugsI Niculescu Duvaz
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: gemtuzumab ozogamicin, Celltech GroupI Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|March 16, 2001
ZD-9331 AstraZenecaI Niculescu-Duvaz
Neoplasma|January 1, 1982
Potential anticancer agents. XXIII. 2. Quantitative structure--activity relationships (QSAR) in the "classical" antifolates areaI Niculescu-Duvaz, T Craescu
The Journal of Clinical Investigation|May 3, 2000
Prodrug-activating systems in suicide gene therapyC J Springer, I Niculescu-Duvaz
Expert Opinion on Investigational Drugs|June 1, 1997
Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinationsI Niculescu-Duvaz, C J Springer
Anti-Cancer Drug Design|July 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugsC J Springer, I Niculescu-Duvaz
Advances in Experimental Medicine and Biology|May 16, 2000
Approaches to gene-directed enzyme prodrug therapy (GDEPT)C J Springer, I Niculescu-Duvaz
Pageof 3